China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary shares at $17.25 each ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public ...

Shares of Ascentage Pharma Group (AAPG) (OTCPK:AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), were trading largely flat Friday following the company's $126M U.S. initial public offering.

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...

Its IPO is one of several on tap for the biotech ... plus royalties of 12% to 19% of net sales. Ascentage Pharma’s Rockville hub, totaling 6,520 square feet, is its only U.S. office.

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

Jan 23 (Reuters) - Ascentage Pharma (6855.HK), opens new tab said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.